Stocksigma LogoStocksigma Logo

Zenith Drugs Confirms Zero Deviation in Preferential Issue Funds Utilization

Zenith Drugs Limited reported no deviation or variation in the utilization of preferential issue proceeds for the half-year ended 30th Sep'26

Zenith Drugs Confirms Zero Deviation in Preferential Issue Funds Utilization

Zenith Drugs Ltd · Others (Uncategorized) · 14 Nov 2026, 9:17 pm

Zenith Drugs Confirms Zero Deviation in Preferential Issue Funds Utilization Zenith Drugs Limited reported no deviation or variation in the utilization of preferential issue proceeds for the half-year ended 30th Sep'26. On 26th Aug'26, the company allotted 16,09,050 convertible warrants to promoters at ₹43.50 per warrant. The company received upfront subscription proceeds of ₹1.75 crore (25% of total consideration at ₹10.88 per warrant), which were fully deployed toward working capital requirements. The remaining 75% exercise price of ₹32.62 per warrant is payable upon equity conversion within an 18-month timeframe.

Original exchange filing (PDF)

More announcements from Zenith Drugs Ltd

All Zenith Drugs Ltd announcements